To identify proteins regulated by OGT and O-GlcNAc cycling that may contribute to CSC phenotypes, we treated MDA-MB-231 breast cancer cells with an OGA inhibitor Thiamet-G (TMG) to block the removal of the modification and increase the extent of protein O-GlcNAcylation. Here, OGA is linked to breast cancer.